Mental HealthICD-10: F20Affects approximately 1% of the global population

Schizophrenia

Schizophrenia is a chronic and severe mental health disorder that affects how a person thinks, feels, and behaves, often making it difficult to distinguish between what is real and what is not. Symptoms typically emerge in late adolescence or early adulthood and include hallucinations, delusions, and disorganized thinking. With ongoing treatment, many people with schizophrenia can manage their symptoms and lead fulfilling lives.

Last updated November 10, 2026

Understanding Schizophrenia

Schizophrenia is a long-term psychiatric illness in which the brain's handling of perception, belief, thought and motivation goes wrong, producing hallucinations and delusions (positive symptoms), flattened emotion and withdrawal (negative symptoms) and problems with attention and memory. It affects about 0.3 to 0.7 percent of people over a lifetime, roughly 24 million worldwide and around 1.5 million adults in the United States. Onset is usually between 16 and 30, a few years earlier in men than women, and is often preceded by months of subtle withdrawal, odd beliefs and falling performance at school or work. Its course varies far more than the stereotype suggests: with sustained treatment about one in seven people meets strict criteria for recovery, many more live independently, and most have periods of stability punctuated by relapse. The biggest threat to life is not psychosis but cardiovascular disease and smoking, which shorten life expectancy by about 15 years, along with a lifetime suicide risk near 5 percent.

The illness is strongly heritable, around 80 percent in twin studies, with more than 280 common gene variants identified, many involving synapses and the immune complement system. Those genes interact with early-life factors such as prenatal infection, obstetric complications, childhood adversity and adolescent cannabis use; daily use of high-potency cannabis raises the odds of psychosis about fivefold. At the chemical level the most consistent finding is excess dopamine release in the striatum, which inflates the sense that ordinary events are significant and is the target of every antipsychotic. Reduced signaling through glutamate NMDA receptors is the leading explanation for negative and cognitive symptoms, and it is the rationale behind trials of NMDA co-agonists such as glycine, sarcosine and N-acetylcysteine. Oxidative stress and low-grade inflammation are measurable and are the other main targets of adjunct research. None of this is a reason to abandon dopamine-blocking medication; it is the reason researchers keep looking for add-ons.

Antipsychotic medication is the foundation of treatment, and the evidence for it is unusually strong. In a 2012 meta-analysis of 65 trials with 6,493 patients, 27 percent of people who stayed on an antipsychotic relapsed within a year compared with 64 percent of those switched to placebo, and continued treatment also reduced hospital admission. The American Psychiatric Association 2020 guideline and NICE both recommend starting medication at the first episode, continuing it, and offering clozapine to the roughly 30 percent whose symptoms do not respond to two other antipsychotics. Medication works best inside coordinated specialty care: in the 404-person RAISE trial, team-based early intervention with family education, supported employment and individual therapy improved symptoms and quality of life, especially when psychosis had gone untreated for less than 74 weeks. The price of antipsychotics is metabolic: olanzapine and clozapine in particular cause weight gain, insulin resistance and high triglycerides, so weight, waist, fasting glucose or A1c, and a lipid panel should be checked at baseline, at 12 weeks and yearly, with metformin considered when weight rises.

Nothing in the natural products aisle treats schizophrenia, and a page that pretended otherwise would be dangerous. What exists is a short list of adjuncts tested on top of medication. N-acetylcysteine has the best record: a 140-person, 24-week trial found it reduced total and negative symptoms, and a 2020 meta-analysis of seven trials confirmed modest benefit that was clearest after six months. Omega-3 had a striking result in 2010, when 12 weeks of fish oil cut conversion to psychosis in 81 high-risk young people from 28 to 5 percent, but the 304-person NEURAPRO replication found no effect, and trials in established illness have been mostly negative. Sarcosine, a glycine transporter inhibitor, improved negative symptoms by 15 to 20 percent in several small 6-week trials of 2 g daily, but the largest glycine trial (157 patients) was negative, and neither helps people on clozapine. Folate modestly improved negative symptoms in a 140-person trial. High-dose niacin and megavitamin regimens failed in 1970s trials, and St John's wort lowers blood levels of several antipsychotics and should be avoided.

The most common and most costly mistake is stopping medication when symptoms settle, usually because the person feels well, dislikes side effects, or has been told by someone that a supplement, diet or cannabis will do the same job. Relapse typically follows within months, each episode is harder to treat than the last, and the risk of hospitalization, job loss and suicide is highest in the period after stopping. If side effects are the problem, the answer is a dose change, a different drug or a long-acting injection, decided with the prescriber, never a quiet taper. The second mistake is ignoring the body: people with schizophrenia are two to three times more likely to have diabetes and heart disease, smoke at two to three times the general rate, and often go years without a glucose or lipid check. Movement, sleep and a yearly metabolic panel are not optional extras; they are what adds the missing years back.

At a Glance

Common symptoms
Auditory or visual hallucinations, Delusions or false beliefs, Disorganized speech and thinking
Main treatments
Antipsychotic medications such as risperidone, olanzapine, or clozapine, Cognitive behavioral therapy adapted for psychosis, Social skills training and supported employment programs
Category
Mental Health · Affects approximately 1% of the global population
See a doctor if
Hearing voices or seeing things others do not

Symptoms

Auditory or visual hallucinations
Delusions or false beliefs
Disorganized speech and thinking
Flat or blunted emotional expression
Social withdrawal and isolation
Difficulty concentrating or paying attention
Impaired memory and executive function
Lack of motivation
Unusual or bizarre behavior
Paranoia

Causes

  • Imbalance of neurotransmitters including dopamine and glutamate
  • Genetic predisposition with multiple genes contributing to risk
  • Abnormalities in brain structure and function
  • Prenatal exposure to viruses, malnutrition, or stress
  • Environmental factors such as childhood trauma or urban upbringing

Risk Factors

  • Family history of schizophrenia or related disorders
  • Prenatal complications or infections
  • Use of psychoactive substances during adolescence
  • Advanced paternal age at conception
  • Highly stressful life events

Diagnosis

  • Comprehensive psychiatric evaluation
  • Structured clinical interviews using DSM-5 criteria
  • Brain imaging such as MRI to rule out other conditions
  • Blood and urine tests to exclude substance use or medical causes
  • Neuropsychological testing

Treatment

  • Antipsychotic medications such as risperidone, olanzapine, or clozapine
  • Cognitive behavioral therapy adapted for psychosis
  • Social skills training and supported employment programs
  • Family psychoeducation and therapy
  • Coordinated specialty care for first-episode psychosis
  • Hospitalization during acute episodes if needed

Natural remedies for schizophrenia: what the evidence says

Ranked by the strength of human evidence for schizophrenia specifically. These sit alongside medical care, not in place of it.

  1. N-Acetylcysteine (NAC)

    Moderate evidence

    In a 140-person, 24-week placebo-controlled trial, 1 g of NAC twice daily added to antipsychotics improved PANSS total, negative and general scores and reduced akathisia, with the gap opening after about 3 months. A 2020 meta-analysis of seven randomized trials found small-to-moderate improvement in total and negative symptoms and in working memory, with benefit concentrated in trials lasting 24 weeks or more. NAC is a glutathione precursor and modulates glutamate; it has never been tested as a stand-alone treatment and should not be used as one.

    Studied dose
    1,000 mg twice daily (2 g/day) alongside antipsychotic medication for at least 24 weeks; some trials used up to 3.6 g/day.
    Cautions
    Nausea, heartburn and loose stools are common at first. Can cause bronchospasm in asthma and may add to the blood-pressure-lowering effect of nitroglycerin. Tell your psychiatrist before starting so symptom changes can be tracked.
  2. Omega-3 Fatty Acids

    Preliminary evidence

    In 81 young people at ultra-high risk of psychosis, 12 weeks of 1.2 g/day omega-3 reduced transition to a psychotic disorder from 27.5 percent to 4.9 percent at one year, with the difference persisting at 7 years. The 304-person NEURAPRO replication found no difference from placebo. In established schizophrenia, trials of 2 to 3 g EPA for 16 weeks and for relapse prevention were negative, while one 71-person first-episode trial found 2.2 g/day for 26 weeks improved symptoms about 50 percent more than placebo. The evidence is mixed and strongest in early illness.

    Studied dose
    1.2 to 2.2 g/day combined EPA and DHA from fish oil, with meals, for at least 12 to 26 weeks.
    Cautions
    Fishy aftertaste and loose stools; at doses above 3 g/day adds to bleeding risk with anticoagulants and antiplatelet drugs. Choose a third-party tested product to limit oxidation and contaminants.
  3. Folate

    Preliminary evidence

    Low folate is common in schizophrenia and correlates with negative symptoms. In a 140-person, 16-week trial, 2 mg folic acid plus 400 mcg vitamin B12 improved negative symptoms versus placebo, but only once a variant in the FOLH1 folate-absorption gene was accounted for. A later 55-person trial of 15 mg L-methylfolate for 12 weeks improved negative and total symptoms regardless of genotype. Effects were modest and these remain single trials.

    Studied dose
    2 mg folic acid with 400 mcg vitamin B12 daily, or 15 mg L-methylfolate daily, for 12 to 16 weeks as an adjunct.
    Cautions
    High-dose folate can mask B12 deficiency and may reduce the effect of methotrexate and some anticonvulsants. Check a B12 level before starting folate alone.
  4. Vitamin D

    Preliminary evidence

    Pooled studies find people with schizophrenia are about twice as likely to be vitamin D deficient, and neonatal deficiency is associated with higher later risk in Danish registry data. Supplementation trials are small and inconsistent: an 8-week trial of 14,000 IU weekly in 47 clozapine-treated patients found no symptom change, while an 80-person, 12-week trial of 50,000 IU every 2 weeks reported improved PANSS scores and insulin sensitivity. Correcting a deficiency is worthwhile for bone and metabolic health; expect little from it psychiatrically.

    Studied dose
    1,000 to 2,000 IU vitamin D3 daily, or a loading schedule set by your clinician if a blood level is below 20 ng/mL.
    Cautions
    Avoid doses above 4,000 IU daily without monitoring. Use caution with thiazide diuretics, and note that antipsychotic-related weight gain can lower vitamin D levels further.
  5. Ginkgo Biloba

    Preliminary evidence

    Tardive dyskinesia, the involuntary movement disorder caused by long-term antipsychotic use, is linked to oxidative damage. In a 157-person, 12-week placebo-controlled trial, 240 mg/day of the standardized extract EGb761 reduced Abnormal Involuntary Movement Scale scores, with 51 percent achieving at least a 30 percent reduction versus 5 percent on placebo. Older Chinese trials of 360 mg/day as an add-on to haloperidol reported symptom improvement, but their quality was mixed. Ginkgo is not a treatment for psychosis itself.

    Studied dose
    240 mg/day standardized extract (EGb761) in divided doses for 12 weeks, for tardive dyskinesia, under psychiatric supervision.
    Cautions
    Raises bleeding risk with warfarin, aspirin and clopidogrel; stop 2 weeks before surgery. May lower the seizure threshold, which matters with clozapine. Avoid in pregnancy.
  6. Melatonin

    Preliminary evidence

    Melatonin has been tested not for psychosis but for the metabolic cost of antipsychotics. In a 48-person, 8-week trial of first-episode patients starting olanzapine, 3 mg of melatonin at night reduced weight gain by about 3 kg and blunted the rise in triglycerides and blood pressure; a second 44-person trial of 5 mg found similar protection. It also improves sleep onset, which is disrupted in most people with schizophrenia, and may ease antipsychotic withdrawal insomnia.

    Studied dose
    3 to 5 mg at bedtime, started alongside a new antipsychotic, for at least 8 weeks.
    Cautions
    Morning grogginess at higher doses. Fluvoxamine raises melatonin blood levels several-fold. Supplement content in the US varies widely from the label, so choose a verified product.

What matters day to day

  • Aim for at least 90 minutes a week of moderate-to-vigorous aerobic exercise: a 2017 meta-analysis found this amount improved global cognition with a moderate effect, alongside reductions in negative symptoms and cardiovascular risk.
  • Ask for weight, waist, blood pressure, fasting glucose or A1c and a lipid panel before starting an antipsychotic, again at 12 weeks and then yearly: this is the APA and ADA monitoring schedule, and it is skipped in more than half of real-world patients.
  • Keep a fixed sleep and wake time and treat insomnia early: short or broken sleep precedes relapse in most people who track it, and CBT for insomnia has been adapted for psychosis with good results.
  • Avoid cannabis, especially high-potency products: continued use after a first episode roughly doubles the relapse rate, and daily high-THC use raises the risk of psychosis about fivefold in the general population.
  • If you smoke and want to quit, tell your prescriber first: stopping raises blood levels of clozapine and olanzapine by 50 percent or more within a week, and varenicline and nicotine replacement are safe and effective in schizophrenia.
  • Keep one trusted person informed of your early warning signs, such as poor sleep, suspiciousness or withdrawing from contact: relapse prevention plans that name specific signs and actions reduce hospital admissions.

Prevention

  • Early intervention at the first signs of psychosis
  • Avoiding recreational drug use, especially cannabis during adolescence
  • Stress management and supportive social environments

When to See a Doctor

  • Hearing voices or seeing things others do not
  • Persistent paranoid or delusional thoughts
  • Significant decline in functioning at work, school, or in relationships
  • Suicidal thoughts or self-harm behaviors

Frequently Asked Questions

References

  1. Keepers GA, Fochtmann LJ, Anzia JM, et al.. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry (2020)
  2. Leucht S, Tardy M, Komossa K, et al.. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet (2012)
  3. Kane JM, Robinson DG, Schooler NR, et al.. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. American Journal of Psychiatry (2016)
  4. Berk M, Copolov D, Dean O, et al.. N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biological Psychiatry (2008)
  5. Yolland CO, Hanratty D, Neill E, et al.. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Australian and New Zealand Journal of Psychiatry (2020)
  6. Amminger GP, Schafer MR, Papageorgiou K, et al.. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry (2010)
  7. McGorry PD, Nelson B, Markulev C, et al.. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry (2017)
  8. Firth J, Stubbs B, Rosenbaum S, et al.. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophrenia Bulletin (2017)
  9. Zhang WF, Tan YL, Zhang XY, et al.. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry (2011)
  10. National Institute of Mental Health. Schizophrenia (2024)View source

Related Conditions

Have questions about Schizophrenia?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.